stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Revenue
Indivior Pharmaceuticals Inc.'s revenue for fiscal 2025 was $1.2B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $1.4B. Over the past ten years it has ranged from $647.0M (fiscal 2020) to $1.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Indivior Pharmaceuticals Inc. ranks 17th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.2B | 4.29% |
| FY2024 | $1.2B | 8.69% |
| FY2023 | $1.1B | 21.31% |
| FY2022 | $901.0M | 13.91% |
| FY2021 | $791.0M | 22.26% |
| FY2020 | $647.0M | (17.58%) |
| FY2019 | $785.0M | (21.89%) |
| FY2018 | $1.0B | (8.05%) |
| FY2017 | $1.1B | 3.31% |
| FY2016 | $1.1B | 4.34% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $356.0M | 3.79% |
| Jun 2026 | $343.0M | 8.20% |
| Mar 2026 | $317.0M | (11.20%) |
| Dec 2025 | $357.0M | 13.69% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| ALKS Alkermes plc compare | $1.8B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| SUPN Indivior Pharmaceuticals Inc. | $1.4B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
| LQDA Liquidia Corporation compare | $450.9M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $87.4M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SUPN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement